An observational study in Tuberculosis, sponsored by Centre for Infectious Disease Research in Zambia. Active, not recruiting at 1 site in Zambia. Open to participants aged 15 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Centre for Infectious Disease Research in Zambia · Observational
The overarching objective/aim of the study is to assess pulmonary TB treatment and longer-term outcomes among people with and without HIV in African population in order to inform policy and practice around TB treatment and create a platform for additional TB research in Zambia
The TB-SRN study will be a prospective observational non-interventional study open to enrollment for individuals ≥15 years of age diagnosed with active pulmonary TB that is either bacteriologically confirmed or clinically diagnosed in HIV-positive and HIV-negative participants. The enrollment will be consecutively, regardless of drug resistance and HIV status. When the sample size of 300 consecutively enrolled TB patients is reached per site, we will enroll additionally drug-resistant TB patients (defined as GeneXpert MTB/RIF positive) until will reach a target of 150 drug resistant TB patients at each site. TB treatment will be managed according to and by the existing standard of care/systems, but those who provide informed consent and agree to participate will contribute other study-related data, which may require additional radiograph(s), laboratory tests, and healthcare-related outcomes measures beyond those collected during routine care. Participants may be co-enrolled in an affiliated or external observational or interventional study
1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.
This study's enrollment of 374 is above the median of 253 across 317 observational studies indexed under Tuberculosis.
Browse Tuberculosis studies →Centre for Infectious Disease Research in Zambia is the lead sponsor of 41 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
553
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of participants achieving successful pulmonary tuberculosis treatment outcome at the end of TB treatment
The proportion of participants who achieve a successful pulmonary tuberculosis treatment outcome at the end of the TB treatment period. Treatment success will be defined according to the study-prespecified TB treatment outcome definitions and will be compared between participants with and without HIV.
Time frame: 4 YEARS
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre for Infectious Disease Research in Zambia